Article
Prognostic Significance of Host- and Tumor-related Factors in Patients with Gastric Cancer
Christof Hottenrott,
Christos Katsios,
Corresponding Author
Christof Hottenrott
Chirurgische Klinik, St. Elisabethenkrankenhaus, Ginnheimer Straße 3, 60487 Frankfurt, Germany
[email protected]Search for more papers by this authorChristos Katsios
Department of Surgery, University Hospital of Ioannina, Stavrou Niarchou Str., 45110 Ioannina, Greece
Search for more papers by this authorChristof Hottenrott,
Christos Katsios,
Corresponding Author
Christof Hottenrott
Chirurgische Klinik, St. Elisabethenkrankenhaus, Ginnheimer Straße 3, 60487 Frankfurt, Germany
[email protected]Search for more papers by this authorChristos Katsios
Department of Surgery, University Hospital of Ioannina, Stavrou Niarchou Str., 45110 Ioannina, Greece
Search for more papers by this authorFirst published: 08 April 2010
No abstract is available for this article.
References
- 1MohriY, TanakaK, OhiM et al. Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg (2010) 34: 285–29010.1007/s00268-009-0302-119997918
- 2ZiogasD, RoukosDH CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer?. Ann Surg Oncol (2009) 16: 2678–268110.1245/s10434-009-0598-y19636637
- 3RoukosDH Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol (2010) 17: 14–1710.1245/s10434-009-0766-019841980
- 4RoukosDH, ParaschouP, LorenzM Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol (2000) 7: 719–72610.1007/s10434-000-0719-011129418
- 5RoukosDH Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol (2009) 16: 795–79810.1245/s10434-009-0317-819169753
- 6RoukosDH Systems medicine: a real approach for future personalized oncology?. Pharmacogenomics (2010) 11(3): 283–28710.2217/pgs.10.3620235782
- 7RoukosDH, ZiogasD From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther (2010) 10(2): 123–12810.1586/era.09.17720131987
- 8RoukosDH Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn (2010) 10(1): 33–4810.1586/erm.09.6920014921
- 9RoukosDH Isolated tumor cells in breast cancer. N Engl J Med (2009) 361: 1994–199510.1056/NEJMc09186119911469
- 10RoukosDH, TzakosA, ZografosG Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther (2009) 9(10): 1413–141610.1586/era.09.11619828000
- 11ZiogasD, RoukosDH Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol (2009) 16(7): 1771–178210.1245/s10434-009-0436-219322611
- 12RoukosDH Genome-wide association studies: how predictable is a person's cancer risk?. Expert Rev Anticancer Ther (2009) 9(4): 389–39210.1586/era.09.1219374592
- 13RoukosDH Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol (2009) 27(8): 1337–133810.1200/JCO.2008.20.281219188673
- 14RoukosDH, ZiogasD Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”?. Ann Surg Oncol (2009) 16(3): 774–77510.1245/s10434-008-0056-218612696
